Serina-AgeX merger to develop treatment for advanced Parkinson’s

Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease. The company will continue under the Serina name and expects to submit an investigational new drug application (IND) for SER-252 to the U.S. Food…